{"schema_version":"secwatch.filing_event.v1","accession":"0001000228-23-000006","form_type":"8-K","ticker":"HSIC","cik":"0001000228","company_name":"HENRY SCHEIN INC","filed_at":"2023-02-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:43.380133+00:00","generated_at":"2026-06-19T08:30:23.034214+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Henry Schein Q4 non-GAAP EPS $1.21 beats year-ago $1.07; guides FY23 $5.25-$5.42","bullets":["Q4 net sales $3.4B, +1.2% as reported; internal sales ex-PPE/COVID test kits +5.0% in local currencies.","GAAP diluted EPS $0.34 (incl. $121M restructuring, $34M impairment) vs $1.05 prior year; non-GAAP $1.21 vs $1.07.","Full-year 2022 non-GAAP EPS $4.81, up from $4.51; FY23 guidance $5.25-$5.42, excluding amortization.","Board authorized additional $400M stock repurchase; Q4 bought ~3.6M shares for $285M at avg $79.55.","Expects FY23 sales growth ~1-3%, PPE/COVID test kit sales to decline ~30-35%; operating margin ~10-15 bps below 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001000228-23-000006","json":"https://secwatch.observer/filing/0001000228-23-000006.json","markdown":"https://secwatch.observer/filing/0001000228-23-000006.md","text":"https://secwatch.observer/filing/0001000228-23-000006.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1000228/000100022823000006/0001000228-23-000006-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1000228/000100022823000006/hsic-20230216.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T08:30:23.034214+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3582c7e2cae87ec81ce71b35da7f08110e8fc1a8","claim":"HENRY SCHEIN INC reported the three months and full year ended December 31, 2022 results: revenue $3.4 billion, net income $46.8 million, or $0.34 per diluted share, EPS $0.34. Guidance initiated.","evidence_excerpt":"-1- more FOR IMMEDIATE RELEASE HENRY SCHEIN REPORTS FOURTH-QUARTER AND FULL-YEAR 2022 FINANCIAL RESULTS AND INTRODUCES 2023 FINANCIAL GUIDANCE ● Fourth-quarter net sales of $3.4 billion increased 1.2% compared with the fourth quarter of 2021; internal sales increased 5.0% in local currencies when excluding sales of personal protective equipment (PPE) products","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1000228/000100022823000006/0001000228-23-000006-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months and full year ended December 31, 2022"},{"label":"Revenue","value":"$3.4 billion"},{"label":"Net income","value":"$46.8 million, or $0.34 per diluted share"},{"label":"EPS","value":"$0.34"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}